In AML, preclinical studies have found that BET inhibitors may be able to successfully block the expression of c-MYC.[6] Significant antiproliferative results were also presented in a study, in which five T-cell lymphoma cell lines were incubated with JQ1, which also resulted in decreased c-MYC levels in all cell lines except one.[7] While various studies have demonstrated the preclinical efficacy of BET inhibition as monotherapy, combination regimens may also be promising. Here, DNER is linked to T-cell non-Hodgkin lymphoma.